Rankings / Cognitive
Cognitive — Prescription Stimulants
Adderall, Vyvanse, modafinil, solriamfetol. Strong evidence in ADHD and narcolepsy, small effects in healthy users, real cardiovascular and dependency risk.
| # | Compound | Ev | Bn | Sf | Grade · Score |
|---|---|---|---|---|---|
| 1 | Centanafadine NDRI / triple reuptake inhibitor (non-stimulant ADHD) | 8 | 5 | 7 | B+ 7.2 |
| 2 | Viloxazine (Qelbree) Non-stimulant ADHD / norepinephrine-serotonin modulator | 8 | 5 | 7 | B+ 7.2 |
| 3 | Bromantane (Ladasten) Russian psychostimulant / actoprotector | 4.5 | 5 | 9 | B 6.4 |
| 4 | Vyvanse (lisdexamfetamine) Prescription stimulant | 8 | 6.5 | 3.5 | B- 6 |
| 5 | Mazindol ER (Quilience) Wakefulness / non-amphetamine stimulant (narcolepsy, ADHD) | 6 | 5 | 5 | C+ 5.5 |
| 6 | Adderall (amphetamine salts) Prescription stimulant | 8 | 6.5 | 2 | C+ 5.4 |
| 7 | Ephedrine / pseudoephedrine / synephrine stimulants Sympathomimetic stimulant | 6 | 5 | 3.5 | C 4.9 |
| 8 | Methylphenidate / phenidate stimulants Prescription stimulant / dopamine-norepinephrine reuptake inhibitor | 6 | 5 | 3.5 | C 4.9 |
These are the prescription wakefulness and ADHD drugs — Adderall, Vyvanse, modafinil, solriamfetol and relatives. They have strong, well-established efficacy for their approved indications, and a much smaller and riskier story as off-label "study drugs" for healthy users. The rankings score both the evidence and the safety cost, which is genuine.
Where the evidence is strong
Amphetamines (Adderall, Vyvanse) and methylphenidate are highly effective in diagnosed ADHD — among the larger effect sizes in psychiatry. Modafinil and armodafinil are well evidenced for narcolepsy and shift-work disorder; solriamfetol and pitolisant address excessive daytime sleepiness. Matched to the right diagnosis, these drugs work and work well.
The healthy-user reality
In people without ADHD, the cognitive benefit is smaller and less consistent than the reputation implies. Modafinil’s effects on rested, healthy users are modest, and amphetamines tend to raise confidence and wakefulness more than actual problem-solving. The trade is real risk: cardiovascular strain, sleep disruption, and dependency, escalating from the wakefulness agents to the Schedule II stimulants.
Scheduling and risk
Most of these are controlled — modafinil and solriamfetol are Schedule IV, the amphetamines Schedule II — and the high-risk banner fires across the tier. Pitolisant is the unusual non-scheduled option. The honest framing is clinician-supervised treatment for a diagnosis, not a casual productivity hack.
Frequently asked
Does modafinil make you smarter?
Not exactly. It promotes wakefulness and clearly helps in sleep-deprived states and narcolepsy, but in rested, healthy users its cognitive effects are modest and inconsistent. It is a Schedule IV prescription drug, not a clean nootropic.
Adderall vs Vyvanse vs modafinil — which is best?
They serve different purposes. Amphetamines (Adderall, Vyvanse) are most effective for diagnosed ADHD but carry the highest dependency and cardiovascular risk (Schedule II); modafinil is better evidenced for wakefulness disorders with a somewhat gentler profile (Schedule IV). "Best" depends on the indication, and all are prescription.
Are study drugs safe for occasional use?
They carry real risks even occasionally — cardiovascular strain, sleep disruption, and dependency potential, highest with the amphetamine-class stimulants. They score with the high-risk banner here, and the honest framing is clinician-supervised treatment, not a productivity tool.
Scores reflect the published evidence, not a recommendation to use any compound or protocol. Nothing here is medical advice. How we score →